MPZL3 and hypohidrotic ectodermal dysplasia: To determine whether knockdown of Mpzl3 expression by ASO exhibits dose‐dependent metabolic effects, we fed a separate cohort of mice HED while simultaneously treating with control ASO (75 mg/kg) or Mpzl3 ASO (25, 50 or 75 mg/kg) twice per week for 7 weeks (IP).